ALISO VIEJO, CA — (Marketwire) — 05/04/12 — (OTCBB: CNSO), which provides information designed to support physicians in identifying the best treatments for mental illnesses, announced today that it has received approvals for the Company-s sixth and seventh U.S. patent and the second Canadian patent. The patents provide additional protection for the company-s neurophysiology-based database and evidence-based tools.
CNS Response has also filed patent applications in the U.S., Europe and Canada related to the Company-s acquisition of patient responsivity data for Transcranial Magnetic Stimulation (TMS). This will strengthen the Company-s current intellectual property position regarding using and identifying neurometric predictors for non-drug therapy. TMS is a non-invasive outpatient procedure that uses magnetic fields to stimulate areas of the brain that are believed to control mood. TMS is approved by the U.S. Food and Drug Administration and offered by approximately 300 psychiatrists nationwide. CNS Response-s new database is designed to help physicians better understand which patients may positively respond to TMS for treating depression. The U.S. and Canadian patent applications are titled “Method for Assessing the Susceptibility of a Human Individual Suffering from a Psychiatric or Neurological Disorder to Neuromodulation Treatment.”
“Our objective is to bring evidence-based tools that reduce trial and error in the treatment of mental health disorders,” said George Carpenter, CNS Response CEO. “Obtaining patents in the field of TMS will extend our intellectual property portfolio to web-enabled devices and to novel, non-drug therapies.”
CNS Response-s recently allowed patent applications are: i) U.S. Patent Application No. 12/575,297, titled “Electroencephalography Based Systems and Methods for Selecting Therapies And Predicting Outcomes,” which was allowed on March 20, 2012 and is expected to be issued by the United States Patent and Trademark Office in June 2012; and ii) U.S. Patent Application No. 11/054,762, titled “EEG Prediction Method For Medication Response,” which was allowed on April 11, 2012 and is expected to be issued by the United States Patent and Trademark Office in July 2012.
This second U.S.-allowed application provides the Company access to a distinctly new patent estate, covering internet transmission of neurometric data; and iii) Canadian Patent, No. 2,452,883, titled “Electroencephalography Based Systems And Methods For Selection Therapies And Predicting Outcomes,” which was issued by the Canadian Intellectual Property Office on January 3, 2012.
Finding the right medication for an individual patient suffering from mental health issues is one of the biggest challenges facing medical professionals. The company-s or allows physicians to compare and learn which medication treatments have been effective, and which have been ineffective for their peers treating patients with similar neurophysiology.
Medical professionals interested in learning more can contact CNS Response at .
CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. While treatment has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorder. The company-s Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company-s original physician-developed database, there are now over 34,000 outcomes for 8,700 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit . Medical professionals interested in learning more can contact CNS Response at .
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company-s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Investor Relations:
Marty Tullio
Managing Partner
McCloud Communications, LLC
949.553.9748 (office)
949.632.1900 (mobile)
Media Relations:
Joyce Johannson
Johannson Communications
612.927.4543 (office)
612.845.3080 (mobile)
You must be logged in to post a comment Login